Clinical Trial Update: Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SHR-1314 for active moderate-to-severe Graves' ophthalmopathy has been terminated, with the update covering its efficacy and safety a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy

Drugs mentioned

• SHR-1314 (SHR-1314)

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Active Moderate to Severe Graves' Orbitopathy | Phase 2 | Status: TERMINATED